chimerix_logo.jpg
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2024 16:31 ET | Chimerix, Inc.
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
chimerix_logo.jpg
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 07:00 ET | Chimerix, Inc.
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
chimerix_logo.jpg
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024 16:05 ET | Chimerix, Inc.
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
chimerix_logo.jpg
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 13, 2024 07:00 ET | Chimerix, Inc.
     – Phase 3 ACTION Study On-Track; First Interim Overall Survival Data Expected Third Quarter 2025 – – ONC206 Phase 1 PK and Safety Data Demonstrate Dose Proportional Exposure with No Dose...
chimerix_logo.jpg
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
August 06, 2024 07:00 ET | Chimerix, Inc.
DURHAM, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024 16:05 ET | Chimerix, Inc.
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to...
chimerix_logo.jpg
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 30, 2024 07:00 ET | Chimerix, Inc.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
chimerix_logo.jpg
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
May 01, 2024 07:00 ET | Chimerix, Inc.
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1...
chimerix_logo.jpg
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
April 24, 2024 07:00 ET | Chimerix, Inc.
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
chimerix_logo.jpg
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024 16:05 ET | Chimerix, Inc.
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards...